Healthcare provider profile · identity verified

Hamidreza Khessali, M.D.

Internal Medicine · RANCHO MIRAGE, CA · NPI 1740682194

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	468	183
Amlodipine Besylate	Amlodipine Besylate	349	136
Rosuvastatin Calcium	Rosuvastatin Calcium	299	114
Levothyroxine Sodium	Levothyroxine Sodium	297	118
Losartan Potassium	Losartan Potassium	297	119
Lisinopril	Lisinopril	271	103
Gabapentin	Gabapentin	179	83
Tamsulosin Hcl	Tamsulosin Hcl	174	63
Omeprazole	Omeprazole	149	84
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	147	33
Metformin Hcl	Metformin Hcl	144	57
Metoprolol Tartrate	Metoprolol Tartrate	130	49
Potassium Chloride	Potassium Chloride	126	50
Metformin Hcl Er	Metformin Hcl	124	54
Atenolol	Atenolol	123	50
Glipizide	Glipizide	109	43
Simvastatin	Simvastatin	104	47
Finasteride	Finasteride	103	27
Meloxicam	Meloxicam	99	58
Pradaxa	Dabigatran Etexilate Mesylate	97	37
Alendronate Sodium	Alendronate Sodium	93	39
Pantoprazole Sodium	Pantoprazole Sodium	86	34
Trazodone Hcl	Trazodone Hcl	81	39
Albuterol Sulfate Hfa	Albuterol Sulfate	79	52
Allopurinol	Allopurinol	79	30
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	78	21
Temazepam	Temazepam	76	suppressed
Prednisone	Prednisone	75	74
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	73	30
Furosemide	Furosemide	70	28
Hydrochlorothiazide	Hydrochlorothiazide	69	32
Jardiance	Empagliflozin	58	20
Triamcinolone Acetonide	Triamcinolone Acetonide	53	31
Fluoxetine Hcl	Fluoxetine Hcl	47	23
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	46	16
Sertraline Hcl	Sertraline Hcl	45	14
Lorazepam	Lorazepam	43	11
Terazosin Hcl	Terazosin Hcl	43	23
Alprazolam	Alprazolam	42	12
Escitalopram Oxalate	Escitalopram Oxalate	41	15
Metoprolol Succinate	Metoprolol Succinate	41	13
Eliquis	Apixaban	40	11
Duloxetine Hcl	Duloxetine Hcl	39	19
Ozempic	Semaglutide	39	11
Carvedilol	Carvedilol	38	13
Clopidogrel	Clopidogrel Bisulfate	37	15
Spironolactone	Spironolactone	37	15
Acetaminophen-Codeine	Acetaminophen With Codeine	36	suppressed
Pravastatin Sodium	Pravastatin Sodium	36	suppressed
Famotidine	Famotidine	35	13
Clonazepam	Clonazepam	34	suppressed
Hydrocortisone	Hydrocortisone	33	16
Quetiapine Fumarate	Quetiapine Fumarate	32	15
Donepezil Hcl	Donepezil Hcl	31	11
Ezetimibe	Ezetimibe	31	14
Zolpidem Tartrate	Zolpidem Tartrate	31	suppressed
Tramadol Hcl	Tramadol Hcl	30	15
Arexvy	Rsvpref3 Antigen/As01e/Pf	28	28
Naproxen	Naproxen	28	23
Morphine Sulfate Er	Morphine Sulfate	27	suppressed
Propranolol Hcl	Propranolol Hcl	26	suppressed
Topiramate	Topiramate	26	suppressed
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	25	25
Doxycycline Monohydrate	Doxycycline Monohydrate	25	20
Fenofibrate	Fenofibrate	24	suppressed
Humulin N	Insulin Nph Human Isophane	24	11
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	24	15
Ondansetron Odt	Ondansetron	24	19
Ropinirole Hcl	Ropinirole Hcl	24	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	24	11
Azelastine Hcl	Azelastine Hcl	23	suppressed
Azithromycin	Azithromycin	23	23
Estradiol	Estradiol	22	13
Montelukast Sodium	Montelukast Sodium	22	suppressed
Sucralfate	Sucralfate	22	11
Hydroxyzine Hcl	Hydroxyzine Hcl	21	11
Alvesco	Ciclesonide	20	13
Cefadroxil	Cefadroxil	20	19
Fluticasone Propionate	Fluticasone Propionate	20	suppressed
Hydralazine Hcl	Hydralazine Hcl	20	suppressed
Citalopram Hbr	Citalopram Hydrobromide	19	suppressed
Fentanyl	Fentanyl	19	suppressed
Naloxone Hcl	Naloxone Hcl	19	12
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	19	suppressed
Chlorhexidine Gluconate	Chlorhexidine Gluconate	18	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	18	suppressed
Nitroglycerin	Nitroglycerin	18	suppressed
Shingrix	Varicella-Zoster Ge/As01b/Pf	18	16
Acyclovir	Acyclovir	17	suppressed
Chlorthalidone	Chlorthalidone	17	suppressed
Colchicine	Colchicine	17	suppressed
Metronidazole	Metronidazole	17	16
Olanzapine	Olanzapine	17	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	16	14
Ciprofloxacin Hcl	Ciprofloxacin Hcl	16	15
Glipizide-Metformin	Glipizide/Metformin Hcl	16	suppressed
Memantine Hcl	Memantine Hcl	16	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	16	suppressed
Oxycodone Hcl	Oxycodone Hcl	16	suppressed
Spiriva Respimat	Tiotropium Bromide	16	suppressed
Baclofen	Baclofen	15	suppressed
Dabigatran Etexilate	Dabigatran Etexilate Mesylate	15	13
Latanoprost	Latanoprost	15	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	15	suppressed
Terbinafine Hcl	Terbinafine Hcl	15	suppressed
Bupropion Xl	Bupropion Hcl	14	suppressed
Ibuprofen	Ibuprofen	14	suppressed
Lactulose	Lactulose	14	suppressed
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	13	suppressed
Rizatriptan	Rizatriptan Benzoate	13	suppressed
Tizanidine Hcl	Tizanidine Hcl	13	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	13	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	12	suppressed
Lansoprazole	Lansoprazole	12	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	11	suppressed
Buspirone Hcl	Buspirone Hcl	11	suppressed
Clonidine Hcl	Clonidine Hcl	11	suppressed
Fluconazole	Fluconazole	11	suppressed
Humulin N Kwikpen	Insulin Nph Human Isophane	11	suppressed
Mirtazapine	Mirtazapine	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error